Advertisement

Rheumatology International

, Volume 39, Issue 6, pp 991–999 | Cite as

ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts

  • José RosasEmail author
  • Carlos Sánchez-Piedra
  • Mónica Fernández-Castro
  • José Luis Andreu
  • Víctor Martínez-Taboada
  • Alejandro Olivé
  • SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)
Cohort Studies

Abstract

The objective of the study was to assess the ESSDAI index characteristics in the SJÖGRENSER cohort (Spanish Rheumatology Association’s registry of patients with Primary Sjögren Syndrome [PSS]). SJÖGRENSER is a prospective multicentric study on a cohort of Spanish patients with PSS who meet the 2002 American–European consensus from rheumatology units. 298 variables were studied in patients for the inclusion of the study from an anonymous list from each department. The ESSDAI (EULAR Sjögren’s syndrome disease activity index) includes 12 domains and measures systematic activity in PSS patients. Each domain is divided into 3–4 levels, (0: no activity; 1: low activity; 2: moderate activity; 3: high activity) and is attributed a weight. Each domain score is obtained by multiplying the activity level by the weight assigned. According to ESSDAI: low activity < 5; moderate activity 5–13, and high activity ≥ 14. ESSDAI was compared between several European PSS cohorts (EULAR, ASSES, GEAS, GRISS, Ducth). 437 patients were included from 33 Spanish rheumatology units. 95.2% were women with a median age of 58.63 years [p25–p75: 50.02–67.98 years] and average PSS evolution of 10.4 years (6–16 years). ESSDAI median on entering the study was 2 (0–4). 31% of patients had ESSDAI 0; low activity 49%, moderate activity 15%, and high activity 5%. Those with greater activity were the joint, haematological and biological domains, whereas the lung was the most affected organ with pleural and parenchymatous involvement. Unlike other European cohorts, the initial SJÖGRENSER cohort was characterised by low-zero systemic activity in 80% of patients, which differentiates it from other cohorts and provides a prospective study opportunity.

Keywords

ESSDAI Primary Sjögren syndrome SJÖGRENSER Cohort study 

Notes

Acknowledgements

Collaborating researchers SJÖGRENSER group: Raúl Menor (Hospital General Jerez de la Frontera, Jerez de la Frontera). Beatriz Rodríguez (Hospital Universitario de Canarias, Santa Cruz de tenerife). Ángel García Aparicio (Hospital Virgen de la Salud, Toledo). Francisco Javier López Longo (Hospital Gregorio Marañón, Madrid). Sara Manrique-Arija (Hospital Carlos Haya, Málaga). Jesús Alberto García Vadillo (Hospital de la Princesa, Madrid). Susana Gil Barato (Hospital General de Alicante, Alicante). Ruth López-González (Hospital Virgen de la Concha, Zamora). Francisco Javier Narváez (Hospital de Bellvitge, Barcelona). Carlos Galisteo (Hospital Parc-Taulí, Sabadell). Jorge González Martín (Hospital Madrid Norte Sanchinarro, Madrid). Esther Ruiz Lucea (Hospital de Basurto, Basurto). Antonio Naranjo, Celia Erausquin, Iñigo Rúa-Figueroa (Hospital Doctor Negrín, Las Palmas de Gran Canaria). Óscar Illera (Hospital Infanta Sofía, Madrid). Lurdes Romani (Hospital Virgen de las Nieves, Granada). Sheila Melchor (Hospital Doce de Octubre, Madrid). Begoña Moreira (Hospital de Sierrallana, Torrelavega). Enrique Raya (Hospital Clínico San Cecilio, Granada). Marina Rodríguez López, Coral Mouriño, Jose María Pego (Hospital de Meixoeiro, Vigo). Natalia Cid (Hospital de Valme, Sevilla). Enrique Júdez (Hospital de Albacete, Albacete). Clara Moriano (Hospital de León, León). Vicente Torrente (Hospital de L’Hospitalet, Hospitalet de Llobregat). Hèctor Corominas (Hospital Sant Joan Despí Moisès Broggi, Barcelona). Blanca García Magallón (Hospital Miguel Servet, Zaragoza). Carlos Guillén Astete (Hospital Ramón y Cajal, Madrid). Ivan Castellvi (Hospital San Pau y Santa Creu, Barcelona). Cristina Bohórquez (Hospital Príncipe de Asturias, Alcalá de Henares), Javier Loricera (Hospital Marqués de Valdecilla, Santander), Joaquín Belzunegui (Hospital de Donostia, Gipuzkoa), Tatiana Cobo (Hospital Infanta Sofia, Madrid). Spain.

Compliance with ethical standards

Conflict of interest

None of the authors declare that they have conflict of interest in relation to this manuscript.

References

  1. 1.
    FoxX RI (2005) Sjögren’s syndrome. Lancet 366:321–331CrossRefGoogle Scholar
  2. 2.
    Moutsopoulos (1994) Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 72:162–165CrossRefPubMedGoogle Scholar
  3. 3.
    Aagyropoulou O, Valentini E, Ferro F et al (2018) One year in review 2018: Sjögren's syndrome. Clin Exp Rheumatol 36(Suppl 112):27–28Google Scholar
  4. 4.
    Qin B, Wang J, Yang Z et al (2015) Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. Ann Rheum Dis 74:1983–1989CrossRefPubMedGoogle Scholar
  5. 5.
    Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109CrossRefPubMedGoogle Scholar
  6. 6.
    Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75:382–389CrossRefPubMedGoogle Scholar
  7. 7.
    Souza FB, Porfirio GJ, Andriolo BN et al (2016) Rituximab effectiveness and safety for treating primary Sjögren’s Syndrome (pSS): systematic review and meta-analysis. PLoS One 11:e0150749CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Carubbi F, Cipriani P, Marelli A et al (2013) Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 15:R172CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mekinian A, Ravaud P, Hatron PY et al (2012) Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87CrossRefPubMedGoogle Scholar
  10. 10.
    Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the autoimmune and Rituximab registry. Ann Rheum Dis 72:1026–1031CrossRefPubMedGoogle Scholar
  11. 11.
    Meiners PM, Arends S, Brouwer E et al (2012) Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis 71:1297–1302CrossRefPubMedGoogle Scholar
  12. 12.
    Seror R, Mariette X, Bowman S et al (2010) Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 62:551–558CrossRefGoogle Scholar
  13. 13.
    Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 87:210–219CrossRefPubMedGoogle Scholar
  14. 14.
    Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fernández Castro M, Andreu JL, Sánchez-Piedra C et al (2016) Sjögren-SER: National registry of the Spanish Society of Rheumatology of patients with primary Sjögren syndrome: objectives and methodology. Reumatol Clin 12:184–189CrossRefPubMedGoogle Scholar
  16. 16.
    Seror R, Bowman SJ, Brito-Zerón P et al (2015) EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 1:e000022CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gottenberg JE, Seror R, Micelli-Richard C et al (2013) Serum levels of Beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s Syndrome. Data at enrollment in the prospective ASSESS Cohort. PLoS One 8:e59868.  https://doi.org/10.1371/journal.pone.0059868 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ramos-Casals M, Brito-Zerón P, Solans R et al (2014) Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 53:321–331CrossRefPubMedGoogle Scholar
  19. 19.
    Quartuccio L, Baldini C, Priori R et al (2017) Cryoglobulinemia in Sjögren's Syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol 44:1179–1183CrossRefPubMedGoogle Scholar
  20. 20.
    Risselada AO, Kruize AA, Bijlsma JWJ (2012) Clinical applicability of the EULAR Sjögren’s syndrome disease activity index: a cumulative ESSDAI score adds in describing disease severity. Ann Rheum Dis 71:631–632CrossRefPubMedGoogle Scholar
  21. 21.
    Moerman RV, Arends S, Meiners PM et al (2014) EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomized controlled trial. Ann Rheum Dis 73:472–474CrossRefPubMedGoogle Scholar
  22. 22.
    Mariette X, Roux S, Zhang J et al (2003) The level of BLyS (BAFF) correlates with the titer of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 62:168–171CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    De Vita S, Quartuccio L, Seror R et al (2015) Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology. (Oxford) 54:2249–2256Google Scholar
  24. 24.
    Quartuccio L, Salvin S, Corazza L et al (2016) Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 34:311–314PubMedGoogle Scholar
  25. 25.
    Meiners PM, Vissink A, Kroese FG et al (2014) Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:1393–1396CrossRefPubMedGoogle Scholar
  26. 26.
    Dumusc A, Wan-Fai NG, James K et al (2018) Comparison of ESSDAI and ClinESSDAI in potential optimization of trial outcomes in primary Sjögren’s syndrome: examination of data from the UK Primary Sjögren’s Syndrome Registry. Swiss Med Wkly 148:w14588PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Rheumatology DepartmentHospital Marina BaixaAlicanteSpain
  2. 2.Research UnitSpanish Society of RheumatologyMadridSpain
  3. 3.Rheumatology DepartmentHospital Universitario Puerta de Hierro MajadahondaMadridSpain
  4. 4.Rheumatology DepartmentHospital Marqués de ValdecillaSantanderSpain
  5. 5.Facultad de MedicinaUniversidad de CantabriaSantanderSpain
  6. 6.Rheumatology DepartmentHospital Germans Trias i PujolBarcelonaSpain

Personalised recommendations